BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Inc. (NASDAQ:XERS) 2/13/19 $60.0 $268.9 $308.2 15% MacroGenics Inc. (NASDAQ:MGNX) 2/12/19 $126.5 $971.7 $828.2 -15% Anchiano Therapeutics Inc....
BioCentury | Feb 15, 2019
Financial News

Anchiano prices $30.5M NASDAQ offering

...name from BioCanCell Ltd. in August 2018. Anchiano Therapeutics Ltd. (Tel Aviv:ANCN; NASDAQ:ANCN), Jerusalem, Israel Paul Bonanos Anchiano Therapeutics Inc....
BioCentury | Feb 12, 2019
Financial News

Anchiano slips after NASDAQ offering

...and LifeSci Capital. Anchiano changed its name from BioCanCell Ltd. in August 2018. Paul Bonanos inodiftagene vixteplasmid (BC-819) Anchiano Therapeutics Inc. BioCanCell...
BioCentury | Jan 11, 2019
Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

...Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN...
...12%. The offering is underwritten by Oppenheimer and Ladenburg Thalmann. Anchiano changed its name from BioCanCell...
...Calif. Poseida Therapeutics Inc., San Diego, Calif. Anchiano Therapeutics Inc. (Tel Aviv:ANCN), Cambridge, Mass. Hongjiang Li AL001 AL002 inodiftagene vixteplasmid (BC-819) P-BCMA-101 Alector Inc. Anchiano Therapeutics Inc. Poseida...
BioCentury | Jan 8, 2019
Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

...Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN...
...Ladenburg Thalmann. Anchiano changed its name from BioCanCell Ltd. in August 2018. Hongjiang Li AL001 AL002 inodiftagene vixteplasmid (BC-819) P-BCMA-101 Alector Inc. Anchiano Therapeutics Inc. Poseida...
BioCentury | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

...Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cardiovascular

...vectors. Next steps could include identifying the optimal combination of Treg-secreted factors to treat MI. BioCanCell...
BioCentury | Mar 8, 2018
Company News

Management tracks: Takeda, Nimbus

...Inc. (Cambridge, Mass.) promoted Christina Isacson to CBO from VP of business development. Cancer company BioCanCell...
BioCentury | Feb 16, 2018
Clinical News

BioCanCell reports Phase I/IIa data for BC-819 in bladder cancer

...trial's primary endpoint was safety and the secondary endpoint was rate of recurrence. This year, BioCanCell...
...U.S. to treat bladder cancer. The product is a double-stranded DNA plasmid encoding diphtheria toxin. BioCanCell...
...recurrence Status: Final Phase I/IIa data Milestone: Start Phase III (2018) Jennie Walters BC-819 American Society of Clinical Oncology BioCanCell...
BioCentury | Jan 5, 2018
Company News

BioCanCell shareholders turn down offer to go private

...its largest shareholder Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) to take BioCanCell private. According to BioCanCell...
...for the tender to be accepted, only 1.4 million shares voted to accept the proposal. BioCanCell's...
...treat non-muscle invasive bladder cancer (NMIBC). BC-819 is a double-stranded DNA plasmid encoding diphtheria toxin. BioCanCell...
Items per page:
1 - 10 of 28
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Inc. (NASDAQ:XERS) 2/13/19 $60.0 $268.9 $308.2 15% MacroGenics Inc. (NASDAQ:MGNX) 2/12/19 $126.5 $971.7 $828.2 -15% Anchiano Therapeutics Inc....
BioCentury | Feb 15, 2019
Financial News

Anchiano prices $30.5M NASDAQ offering

...name from BioCanCell Ltd. in August 2018. Anchiano Therapeutics Ltd. (Tel Aviv:ANCN; NASDAQ:ANCN), Jerusalem, Israel Paul Bonanos Anchiano Therapeutics Inc....
BioCentury | Feb 12, 2019
Financial News

Anchiano slips after NASDAQ offering

...and LifeSci Capital. Anchiano changed its name from BioCanCell Ltd. in August 2018. Paul Bonanos inodiftagene vixteplasmid (BC-819) Anchiano Therapeutics Inc. BioCanCell...
BioCentury | Jan 11, 2019
Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

...Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN...
...12%. The offering is underwritten by Oppenheimer and Ladenburg Thalmann. Anchiano changed its name from BioCanCell...
...Calif. Poseida Therapeutics Inc., San Diego, Calif. Anchiano Therapeutics Inc. (Tel Aviv:ANCN), Cambridge, Mass. Hongjiang Li AL001 AL002 inodiftagene vixteplasmid (BC-819) P-BCMA-101 Alector Inc. Anchiano Therapeutics Inc. Poseida...
BioCentury | Jan 8, 2019
Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

...Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN...
...Ladenburg Thalmann. Anchiano changed its name from BioCanCell Ltd. in August 2018. Hongjiang Li AL001 AL002 inodiftagene vixteplasmid (BC-819) P-BCMA-101 Alector Inc. Anchiano Therapeutics Inc. Poseida...
BioCentury | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

...Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc...
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cardiovascular

...vectors. Next steps could include identifying the optimal combination of Treg-secreted factors to treat MI. BioCanCell...
BioCentury | Mar 8, 2018
Company News

Management tracks: Takeda, Nimbus

...Inc. (Cambridge, Mass.) promoted Christina Isacson to CBO from VP of business development. Cancer company BioCanCell...
BioCentury | Feb 16, 2018
Clinical News

BioCanCell reports Phase I/IIa data for BC-819 in bladder cancer

...trial's primary endpoint was safety and the secondary endpoint was rate of recurrence. This year, BioCanCell...
...U.S. to treat bladder cancer. The product is a double-stranded DNA plasmid encoding diphtheria toxin. BioCanCell...
...recurrence Status: Final Phase I/IIa data Milestone: Start Phase III (2018) Jennie Walters BC-819 American Society of Clinical Oncology BioCanCell...
BioCentury | Jan 5, 2018
Company News

BioCanCell shareholders turn down offer to go private

...its largest shareholder Clal Biotechnology Industries Ltd. (Tel Aviv:CBI) to take BioCanCell private. According to BioCanCell...
...for the tender to be accepted, only 1.4 million shares voted to accept the proposal. BioCanCell's...
...treat non-muscle invasive bladder cancer (NMIBC). BC-819 is a double-stranded DNA plasmid encoding diphtheria toxin. BioCanCell...
Items per page:
1 - 10 of 28